| Objective:To investigate the risk factors of extrapulmonary infection induced by carbapenem-resistant Acinetobacter baumannii (CRAB) and observe the clinical outcomes of cefoperazone/sulbactam in the treatment of CRAB infections in our hospital.Methods:17patients with CRAB infections who were treated with cefoperazone/sulbactam monotherapy or combination therapy from May1,2011to December31,2012in Sir Run Run Shaw Hospital were chose to conduct a retrospective study. Underlying diseases, clinical risk factors for infection, sites of infection, duration of treatment, clinical efficacy and bacterial clearance were analysed.Results:he mean age of patients was64.18±11.69years, and15patients (88.24%) were male. The average length of stay at hospital was48.24±26.61days. Bloodstream infection and intraperitoneal infection were main infections (35.29%and29.41%, respectively). All patients had histories of central venous catheter insertion and prior antibiotic therapy15patients (88.24%) used carbapenem antibiotics,16patients (94.12%) had been admitted to ICU,16patients (70.59%) received mechanical ventilation and11patients (64.71%)of underwent surgeries.7patients accepted cefoperazone/sulbactam monotherapy, while10patients combination therapy. Mean duration of treatment was13days.14cases (82.35%) showed positive clinical responses(85.71%in the monotherapy group,80%in the combination therapy group).However, the microbial success rates was52.94%(71.43%in the monotherapy group,40%in the combination therapy group). No statistically significant differences were found between monotherapy and combination groups(P>0.05).Conclusion:Cefoperazone/sulbactam were effective to CRAB infection. The combination therapy did not show better clinical and microbial success rates than the monotherapy. We still need large samples clinical cases randomized controlled studies to investigate the clinical outcomes of cefoperazone/sulbactam monotherapy or combination therapy against CRAB infection. |
PDF Full Text Request